- Home
- ADIL vs MYNZ Comparison
ADIL vs MYNZ Comparison
Compare ADIL & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- MYNZ
- Stock Information
- Founded
- ADIL 2010
- MYNZ 2021
- Country
- ADIL United States
- MYNZ Germany
- Employees
- ADIL N/A
- MYNZ N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- ADIL Health Care
- MYNZ Health Care
- Exchange
- ADIL Nasdaq
- MYNZ Nasdaq
- Market Cap
- ADIL 6.5M
- MYNZ 6.1M
- IPO Year
- ADIL 2018
- MYNZ 2021
- Fundamental
- Price
- ADIL $1.06
- MYNZ $0.24
- Analyst Decision
- ADIL Strong Buy
- MYNZ Buy
- Analyst Count
- ADIL 1
- MYNZ 2
- Target Price
- ADIL $8.00
- MYNZ $3.00
- AVG Volume (30 Days)
- ADIL 222.2K
- MYNZ 5.2M
- Earning Date
- ADIL 11-13-2024
- MYNZ 11-26-2024
- Dividend Yield
- ADIL N/A
- MYNZ N/A
- EPS Growth
- ADIL N/A
- MYNZ N/A
- EPS
- ADIL N/A
- MYNZ N/A
- Revenue
- ADIL N/A
- MYNZ $917,203.00
- Revenue This Year
- ADIL N/A
- MYNZ $36.69
- Revenue Next Year
- ADIL N/A
- MYNZ $91.67
- P/E Ratio
- ADIL N/A
- MYNZ N/A
- Revenue Growth
- ADIL N/A
- MYNZ 16.23
- 52 Week Low
- ADIL $0.77
- MYNZ $0.19
- 52 Week High
- ADIL $4.17
- MYNZ $1.79
- Technical
- Relative Strength Index (RSI)
- ADIL 52.82
- MYNZ 45.71
- Support Level
- ADIL $0.98
- MYNZ $0.22
- Resistance Level
- ADIL $1.28
- MYNZ $0.36
- Average True Range (ATR)
- ADIL 0.07
- MYNZ 0.04
- MACD
- ADIL 0.00
- MYNZ 0.00
- Stochastic Oscillator
- ADIL 29.03
- MYNZ 18.59
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.